Research programme: oral biotherapeutics - Intrexon

Drug Profile

Research programme: oral biotherapeutics - Intrexon

Alternative Names: AG015; Antibody-toxin conjugates - Intrexon; Clostridium difficile enteropathy therapeutic - Intrexon; Clostridium difficile-associated enterocolitis therapeutic - Intrexon; Coeliac Disease ActoBiotics™ - ActoGeniX; Coeliac disease therapeutics - Intrexon; IL-10/proinsulin ActoBiotics™; IL-27 - Intrexon; Inflammatory bowel disease ActoBiotics™; Inflammatory bowel disease therapeutics - Intrexon; Interleukin-27 - Intrexon; Lactococcus lactis expressing human interleukin-27; Lactococcus lactis secreting gluten antigens; Lactococcus lactis secreting human interleukin-27; Microbiome ActoBiotics™; Microbiome modulators - Intrexon; Microbiota ActoBiotics™; Microbiota modulators - Intrexon; Peptide-toxin conjugates - Intrexon; Proinsulin/IL-10 ActoBiotic™

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ActoGeniX
  • Developer Intrexon Corporation; Katholieke Universiteit Leuven; National Cancer Institute (USA); Synthetic Biologics
  • Class Antigens; Bacteria; Cytokines; Hormones; Monoclonal antibodies; Peptides; Recombinant proteins
  • Mechanism of Action Bacterial toxin inhibitors; Enzyme replacements; Helper-inducer T-lymphocyte modulators; Immunomodulators; Immunosuppressants; Interleukin 27 replacements; Microbiome modulators; Regulatory T-lymphocyte stimulants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Coeliac disease; Type 1 diabetes mellitus

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Research Digestive system disorders; Phenylketonuria
  • No development reported Coeliac disease; Inflammatory bowel diseases
  • Discontinued Clostridium-difficile-infections

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Coeliac disease in USA (PO, Capsule)
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Belgium (PO, Capsule)
  • 29 Jan 2018 Discontinued for Clostridium difficile infections in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top